Roivant Sciences Ltd. (ROIV) Bundle
A Brief History of Roivant Sciences Ltd. (ROIV)
Company Overview
Roivant Sciences Ltd. is a biopharmaceutical company founded in 2014 by Vivek Ramaswamy. The company is headquartered in New York City.
Financial Performance
| Fiscal Year | Revenue | Net Income/Loss |
|---|---|---|
| 2022 | $195.4 million | ($331.1 million) |
| 2023 | $268.3 million | ($276.5 million) |
Stock Information
Ticker Symbol: ROIV
Initial Public Offering (IPO) Date: September 14, 2021
IPO Price: $15 per share
Key Subsidiaries
- Axovant Gene Therapies
- Enzyvant Therapeutics
- Urovant Sciences
- Altavant Sciences
- Dermavant Sciences
Research and Development Focus
Primary therapeutic areas include neurology, rare diseases, dermatology, and gene therapies.
Corporate Milestones
| Year | Key Event |
|---|---|
| 2014 | Company founded by Vivek Ramaswamy |
| 2021 | Merged with Montes Archimedes Acquisition Corp |
| 2023 | Completed multiple clinical-stage asset acquisitions |
Investor Information
Market Capitalization (as of January 2024): $1.2 billion
Number of Employees: Approximately 450
Research Pipeline
- Currently has 10+ clinical-stage assets
- Multiple programs in Phase 2 and Phase 3 clinical trials
- Focused on rare disease and neurological treatments
A Who Owns Roivant Sciences Ltd. (ROIV)
Major Shareholders
| Shareholder | Ownership Percentage | Number of Shares |
|---|---|---|
| Vivek Ramaswamy | 17.4% | 22,543,000 shares |
| Vanguard Group Inc. | 7.2% | 9,320,000 shares |
| BlackRock Inc. | 5.9% | 7,630,000 shares |
Institutional Ownership
As of Q4 2023, institutional investors hold approximately 62.3% of Roivant Sciences Ltd. total outstanding shares.
Top Institutional Investors
- Vanguard Group Inc.: 7.2% ownership
- BlackRock Inc.: 5.9% ownership
- Fidelity Management & Research: 4.6% ownership
- Renaissance Technologies LLC: 3.8% ownership
Founder Ownership
Vivek Ramaswamy remains the largest individual shareholder with 17.4% of total shares.
Public Ownership
Roivant Sciences Ltd. is a publicly traded company on the NASDAQ, with 37.7% of shares available to public retail investors.
Roivant Sciences Ltd. (ROIV) Mission Statement
Company Overview
Roivant Sciences Ltd. is a biopharmaceutical company founded in 2014 by Vivek Ramaswamy. The company is headquartered in New York City, with a market capitalization of $1.37 billion as of January 2024.
Mission Statement Components
- Develop innovative therapeutic solutions across multiple medical domains
- Accelerate drug development through technological integration
- Address unmet medical needs through strategic pharmaceutical research
Financial Performance
| Metric | 2023 Value |
|---|---|
| Total Revenue | $356.4 million |
| Net Loss | $487.2 million |
| Research & Development Expenses | $412.6 million |
Key Therapeutic Focus Areas
- Neurology
- Immunology
- Oncology
- Rare Diseases
Pipeline Metrics
| Development Stage | Number of Programs |
|---|---|
| Preclinical | 12 |
| Phase I | 7 |
| Phase II | 5 |
| Phase III | 3 |
Operational Strategy
Key strategic approach: Create independent subsidiary companies (Vants) focused on specific therapeutic areas to accelerate drug development and maximize operational efficiency.
How Roivant Sciences Ltd. (ROIV) Works
Company Overview
Roivant Sciences Ltd. is a biopharmaceutical company founded in 2014 by Vivek Ramaswamy. The company trades on NASDAQ under the ticker ROIV with a market capitalization of approximately $1.2 billion as of January 2024.
Business Model
Roivant operates through a unique "vant" model, creating specialized subsidiary companies focused on specific therapeutic areas.
| Subsidiary | Therapeutic Focus | Key Developments |
|---|---|---|
| Axovant Therapeutics | Neurology | Alzheimer's and dementia research |
| Dermavant Sciences | Dermatology | Tapinarof psoriasis treatment |
| Immunovant | Autoimmune diseases | IMVT-1401 clinical development |
Financial Performance
Financial highlights for 2023:
- Total revenue: $387.4 million
- Net loss: $456.2 million
- Research and development expenses: $312.6 million
Research and Development Strategy
Roivant focuses on developing innovative therapies across multiple disease areas with significant unmet medical needs.
| Pipeline Stage | Number of Programs | Estimated Investment |
|---|---|---|
| Preclinical | 12 | $85.3 million |
| Phase I | 7 | $124.7 million |
| Phase II | 5 | $167.2 million |
| Phase III | 3 | $211.5 million |
Corporate Structure
Key corporate details:
- Headquarters: New York City
- Number of employees: 487
- Public listing: NASDAQ (ROIV)
Key Leadership
Executive team as of 2024:
- Vivek Ramaswamy - Founder
- Matthew Klein - CEO
- Brian Stuglik - Chief Operating Officer
How Roivant Sciences Ltd. (ROIV) Makes Money
Revenue Streams
Roivant Sciences Ltd. generates revenue through multiple channels:
- Pharmaceutical development and licensing
- Collaboration agreements
- Subsidiary business operations
Financial Performance
| Financial Metric | Amount (2023) |
|---|---|
| Total Revenue | $198.4 million |
| Research and Development Expenses | $364.2 million |
| Net Loss | $296.7 million |
Key Subsidiary Platforms
Roivant operates multiple subsidiary platforms:
- Immunovant (Rheumatology)
- Dermavant (Dermatology)
- Arbutus Biopharma (Viral Disease)
- Cytovant (Cell Therapy)
Licensing and Partnership Strategy
Roivant generates revenue through strategic partnerships with pharmaceutical companies, including:
| Partner | Deal Value | Focus Area |
|---|---|---|
| Pfizer | $350 million upfront | Immunology |
| Novartis | $200 million collaboration | Neuroscience |
Venture Capital Investments
Roivant attracts significant venture capital funding:
| Investment Round | Amount Raised | Year |
|---|---|---|
| Series C | $470 million | 2021 |
| Series D | $615 million | 2022 |
Product Pipeline Monetization
Current product pipeline potential:
- Resunab (Dermavant) - Atopic dermatitis treatment
- IMVT-1402 (Immunovant) - Autoimmune disease therapy
Roivant Sciences Ltd. (ROIV) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.